235 related articles for article (PubMed ID: 32908254)
1. Diagnosis of ductal carcinoma in situ in an era of de-escalation of therapy.
Schnitt SJ
Mod Pathol; 2021 Jan; 34(Suppl 1):1-7. PubMed ID: 32908254
[TBL] [Abstract][Full Text] [Related]
2. Avoiding Overtreatment of Ductal Carcinoma in situ.
van der Borden CL; Stoffers S; Lips EH; Wesseling J
Trends Cancer; 2019 Jul; 5(7):391-393. PubMed ID: 31311652
[TBL] [Abstract][Full Text] [Related]
3. The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening.
van Luijt PA; Heijnsdijk EA; Fracheboud J; Overbeek LI; Broeders MJ; Wesseling J; den Heeten GJ; de Koning HJ
Breast Cancer Res; 2016 May; 18(1):47. PubMed ID: 27160733
[TBL] [Abstract][Full Text] [Related]
4. Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.
Delaloge S; Khan SA; Wesseling J; Whelan T
Lancet; 2024 Jun; 403(10445):2734-2746. PubMed ID: 38735296
[TBL] [Abstract][Full Text] [Related]
5. Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care.
Mukhtar RA; Wong JM; Esserman LJ
J Natl Compr Canc Netw; 2015 Jun; 13(6):737-43. PubMed ID: 26085389
[TBL] [Abstract][Full Text] [Related]
6. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).
Groen EJ; Elshof LE; Visser LL; Rutgers EJT; Winter-Warnars HAO; Lips EH; Wesseling J
Breast; 2017 Feb; 31():274-283. PubMed ID: 27671693
[TBL] [Abstract][Full Text] [Related]
7. Update on Management of Ductal Carcinoma in Situ.
Buchheit JT; Schacht D; Kulkarni SA
Clin Breast Cancer; 2024 Jun; 24(4):292-300. PubMed ID: 38216382
[TBL] [Abstract][Full Text] [Related]
8. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
9. Modeling the natural history of ductal carcinoma in situ based on population data.
Chootipongchaivat S; van Ravesteyn NT; Li X; Huang H; Weedon-Fekjær H; Ryser MD; Weaver DL; Burnside ES; Heckman-Stoddard BM; de Koning HJ; Lee SJ
Breast Cancer Res; 2020 May; 22(1):53. PubMed ID: 32460821
[TBL] [Abstract][Full Text] [Related]
10. Should low-risk DCIS lose the cancer label? An evidence review.
Ma T; Semsarian CR; Barratt A; Parker L; Pathmanathan N; Nickel B; Bell KJL
Breast Cancer Res Treat; 2023 Jun; 199(3):415-433. PubMed ID: 37074481
[TBL] [Abstract][Full Text] [Related]
11. Controversies Regarding the Diagnosis and Management of Ductal Carcinoma In Situ.
Levinsohn E; Altman M; Chagpar AB
Am Surg; 2018 Jan; 84(1):1-6. PubMed ID: 29428007
[TBL] [Abstract][Full Text] [Related]
12. Current approach and future perspective for ductal carcinoma in situ of the breast.
Kanbayashi C; Iwata H
Jpn J Clin Oncol; 2017 Aug; 47(8):671-677. PubMed ID: 28486668
[TBL] [Abstract][Full Text] [Related]
13. Addressing overtreatment of screen detected DCIS; the LORIS trial.
Francis A; Thomas J; Fallowfield L; Wallis M; Bartlett JM; Brookes C; Roberts T; Pirrie S; Gaunt C; Young J; Billingham L; Dodwell D; Hanby A; Pinder SE; Evans A; Reed M; Jenkins V; Matthews L; Wilcox M; Fairbrother P; Bowden S; Rea D
Eur J Cancer; 2015 Nov; 51(16):2296-303. PubMed ID: 26296293
[TBL] [Abstract][Full Text] [Related]
14. Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in situ: the pathological perspective.
Jones JL
Breast Cancer Res; 2006; 8(2):204. PubMed ID: 16677423
[TBL] [Abstract][Full Text] [Related]
15. The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification.
Pinder SE; Ellis IO
Breast Cancer Res; 2003; 5(5):254-7. PubMed ID: 12927035
[TBL] [Abstract][Full Text] [Related]
16. Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.
Wright JL; Rahbar H; Obeng-Gyasi S; Carlos R; Tjoe J; Wolff AC
J Clin Oncol; 2022 Jan; 40(3):225-230. PubMed ID: 34813345
[No Abstract] [Full Text] [Related]
17. A Call for Change in the Diagnosis and Treatment of Patients with Ductal Carcinoma In Situ: An Opportunity to Minimize Overdiagnosis and Overtreatment.
Masood S
Breast J; 2015; 21(6):575-8. PubMed ID: 26547899
[No Abstract] [Full Text] [Related]
18. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.
Elshof LE; Tryfonidis K; Slaets L; van Leeuwen-Stok AE; Skinner VP; Dif N; Pijnappel RM; Bijker N; Rutgers EJ; Wesseling J
Eur J Cancer; 2015 Aug; 51(12):1497-510. PubMed ID: 26025767
[TBL] [Abstract][Full Text] [Related]
19. Low-risk DCIS. What is it? Observe or excise?
Pinder SE; Thompson AM; Wesserling J
Virchows Arch; 2022 Jan; 480(1):21-32. PubMed ID: 34448893
[TBL] [Abstract][Full Text] [Related]
20. Ductal carcinoma in situ: treatment or active surveillance?
Kuerer HM
Expert Rev Anticancer Ther; 2015; 15(7):777-85. PubMed ID: 25938920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
